Top-Rated StocksTop-RatedNASDAQ:MRUS Merus (MRUS) Stock Price, News & Analysis $51.74 -0.56 (-1.07%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Merus Stock (NASDAQ:MRUS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Merus alerts:Sign Up Key Stats Today's Range$51.68▼$52.6350-Day Range$47.19▼$53.7152-Week Range$19.81▼$61.61Volume174,091 shsAverage Volume713,063 shsMarket Capitalization$3.04 billionP/E RatioN/ADividend YieldN/APrice Target$82.00Consensus RatingBuy Company OverviewMerus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Read More… Protect Your Bank Account with THESE 4 Simple Steps (Ad)Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. Merus Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks56th Percentile Overall ScoreMRUS MarketRank™: Merus scored higher than 56% of companies evaluated by MarketBeat, and ranked 619th out of 1,013 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingMerus has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMerus has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Merus' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Merus are expected to decrease in the coming year, from ($3.27) to ($3.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Merus is -17.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Merus is -17.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMerus has a P/B Ratio of 8.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Merus' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.15% of the outstanding shares of Merus have been sold short.Short Interest Ratio / Days to CoverMerus has a short interest ratio ("days to cover") of 15.7, which indicates bearish sentiment.Change versus previous monthShort interest in Merus has recently increased by 25.04%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMerus does not currently pay a dividend.Dividend GrowthMerus does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.15% of the outstanding shares of Merus have been sold short.Short Interest Ratio / Days to CoverMerus has a short interest ratio ("days to cover") of 15.7, which indicates bearish sentiment.Change versus previous monthShort interest in Merus has recently increased by 25.04%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.83 News SentimentMerus has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Merus this week, compared to 4 articles on an average week.Search Interest3 people have searched for MRUS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows7 people have added Merus to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Merus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.57% of the stock of Merus is held by insiders.Percentage Held by Institutions96.14% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Merus' insider trading history. Receive MRUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter. Email Address MRUS Stock News HeadlinesInvesting in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gainOctober 17 at 11:28 AM | finance.yahoo.comMerus (NASDAQ:MRUS) Given Consensus Recommendation of "Buy" by AnalystsOctober 14, 2024 | americanbankingnews.comThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election. October 18, 2024 | Porter & Company (Ad)Buy Rating Affirmed for Merus with Promising Outlook on Petosemtamab’s Clinical and Market PotentialOctober 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Merus on Strong Clinical Trial Progress and Competitive PositioningOctober 1, 2024 | markets.businessinsider.comMerus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCCSeptember 30, 2024 | finance.yahoo.comBOXER CAPITAL, LLC Acquires New Stake in Instil Bio IncSeptember 29, 2024 | finance.yahoo.comTimesSquare Capital Management U.S. Small Cap Growth Strategy Established a Position in Merus N.V. (MRUS)September 18, 2024 | msn.comSee More Headlines MRUS Stock Analysis - Frequently Asked Questions How have MRUS shares performed this year? Merus' stock was trading at $27.50 at the beginning of 2024. Since then, MRUS stock has increased by 88.1% and is now trading at $51.74. View the best growth stocks for 2024 here. How were Merus' earnings last quarter? Merus (NASDAQ:MRUS) issued its quarterly earnings results on Thursday, August, 1st. The biotechnology company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by $0.05. The biotechnology company earned $7.33 million during the quarter, compared to analyst estimates of $9.64 million. Merus had a negative trailing twelve-month return on equity of 36.33% and a negative net margin of 476.41%. When did Merus IPO? Merus (MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers. Who are Merus' major shareholders? Merus' top institutional shareholders include Exchange Traded Concepts LLC (0.01%) and nVerses Capital LLC. Insiders that own company stock include Sven Ante Lundberg, Harry Shuman and Peter B Silverman. View institutional ownership trends. How do I buy shares of Merus? Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Merus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Merus investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE), Jabil (JBL) and Disc Medicine (IRON). Company Calendar Last Earnings8/01/2024Today10/17/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MRUS CUSIPN/A CIK1651311 Webwww.merus.nl Phone(130) 253-8800FaxN/AEmployees37Year FoundedN/APrice Target and Rating Average Stock Price Target$82.00 High Stock Price Target$111.00 Low Stock Price Target$45.00 Potential Upside/Downside+58.5%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($2.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-154,940,000.00 Net Margins-476.41% Pretax Margin-460.58% Return on Equity-36.33% Return on Assets-28.68% Debt Debt-to-Equity RatioN/A Current Ratio9.97 Quick Ratio9.97 Sales & Book Value Annual Sales$35.19 million Price / Sales86.28 Cash FlowN/A Price / Cash FlowN/A Book Value$6.17 per share Price / Book8.39Miscellaneous Outstanding Shares58,688,000Free Float65,093,000Market Cap$3.04 billion OptionableOptionable Beta1.11 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:MRUS) was last updated on 10/18/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.